Penumbra (PEN) Competitors $273.54 -2.86 (-1.04%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$298.00 +24.46 (+8.94%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PEN vs. LNTH, ITGR, GEHC, PHG, ZBH, SNN, SOLV, STVN, GKOS, and IRTCShould you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Stevanato Group (STVN), Glaukos (GKOS), and iRhythm Technologies (IRTC). These companies are all part of the "medical" sector. Penumbra vs. Its Competitors Lantheus Integer GE HealthCare Technologies Koninklijke Philips Zimmer Biomet Smith & Nephew SNATS Solventum Stevanato Group Glaukos iRhythm Technologies Penumbra (NYSE:PEN) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk. Does the media refer more to PEN or LNTH? In the previous week, Lantheus had 35 more articles in the media than Penumbra. MarketBeat recorded 46 mentions for Lantheus and 11 mentions for Penumbra. Penumbra's average media sentiment score of 1.03 beat Lantheus' score of 0.45 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 10 Very Positive mention(s) 0 Positive mention(s) 31 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Is PEN or LNTH more profitable? Lantheus has a net margin of 17.82% compared to Penumbra's net margin of 11.54%. Lantheus' return on equity of 34.06% beat Penumbra's return on equity.Company Net Margins Return on Equity Return on Assets Penumbra11.54% 11.55% 8.76% Lantheus 17.82%34.06%19.10% Do insiders and institutionals believe in PEN or LNTH? 88.9% of Penumbra shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 4.2% of Penumbra shares are held by insiders. Comparatively, 2.0% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation & earnings, PEN or LNTH? Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPenumbra$1.28B8.33$14.01M$3.7672.75Lantheus$1.53B2.35$312.44M$3.7614.08 Which has more risk & volatility, PEN or LNTH? Penumbra has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Do analysts rate PEN or LNTH? Penumbra currently has a consensus target price of $302.93, indicating a potential upside of 10.75%. Lantheus has a consensus target price of $91.60, indicating a potential upside of 73.03%. Given Lantheus' higher possible upside, analysts plainly believe Lantheus is more favorable than Penumbra.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Penumbra 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88Lantheus 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryPenumbra and Lantheus tied by winning 8 of the 16 factors compared between the two stocks. Get Penumbra News Delivered to You Automatically Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEN vs. The Competition Export to ExcelMetricPenumbraMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$10.67B$6.78B$5.78B$21.54BDividend YieldN/A1.20%5.73%3.49%P/E Ratio72.7526.0175.4629.75Price / Sales8.33187.86466.5051.72Price / Cash94.4822.1825.8118.13Price / Book9.125.0012.164.63Net Income$14.01M$176.38M$3.29B$999.94M7 Day Performance-4.07%0.64%0.73%0.62%1 Month Performance8.12%2.47%4.41%4.34%1 Year Performance46.32%10.96%62.61%16.38% Penumbra Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PENPenumbra4.5546 of 5 stars$273.54-1.0%$302.93+10.7%+46.3%$10.67B$1.28B72.754,500LNTHLantheus4.5479 of 5 stars$54.90-1.1%$105.50+92.2%-49.8%$3.73B$1.53B14.60700Trending NewsShort Interest ↓ITGRInteger3.9901 of 5 stars$107.58+0.2%$140.25+30.4%-19.9%$3.77B$1.72B47.3911,000Positive NewsGEHCGE HealthCare Technologies4.3117 of 5 stars$73.73+0.0%$88.55+20.1%-12.0%$33.66B$19.67B15.1153,000News CoveragePositive NewsPHGKoninklijke Philips3.3268 of 5 stars$27.59+0.0%N/A-8.2%$26.56B$19.50B145.1866,678Short Interest ↓ZBHZimmer Biomet4.8074 of 5 stars$106.11+1.0%$111.44+5.0%-2.9%$21.02B$7.68B25.8217,000Positive NewsSNNSmith & Nephew SNATS3.1228 of 5 stars$37.47+0.7%$36.00-3.9%+19.9%$16.41B$5.94B17.3517,349News CoverageSOLVSolventum2.0983 of 5 stars$73.15+0.7%$85.75+17.2%+4.7%$12.68B$8.25B33.8622,000Positive NewsSTVNStevanato GroupN/A€23.14-1.4%N/A+37.2%€7.01B€1.19B42.855,521News CoveragePositive NewsGKOSGlaukos4.7077 of 5 stars$95.86-0.7%$127.42+32.9%-34.5%$5.50B$383.48M-58.10780News CoveragePositive NewsAnalyst ForecastIRTCiRhythm Technologies1.3315 of 5 stars$169.98-0.9%$163.82-3.6%+134.7%$5.46B$591.84M-58.012,000News CoveragePositive News Related Companies and Tools Related Companies Lantheus Competitors Integer Competitors GE HealthCare Technologies Competitors Koninklijke Philips Competitors Zimmer Biomet Competitors Smith & Nephew SNATS Competitors Solventum Competitors Stevanato Group Competitors Glaukos Competitors iRhythm Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PEN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Penumbra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
